During this week, I found out that the U.S. Food and Drug Adminstration has given Vertex and CRISPR Therapeutics the approval to use Casgevy as a cure for patients with Beta-Thalassemia 12 years and older. This is the latest sign the gene and cell therapy market is maturing. This market is likely to grow to more than $80 billion over the next 10 years or so.
This comes after a few weeks they approved Casgevy to treat patients with sickle cell disease. Simultaneously, Bluebird Bio was given approval from the FDA for Lyfgenia, its gene therapy for sickle cell. In November, the MHRA granted conditional marketing authorisation for Casgevy in both Sickle Cell Disease and TDT.
With this nod, Casgevy is expected to be approved for more diseases in the coming months,. Several of which are already in Phase II or III, including cancers and amyloidosis.